Xeris Biopharma (XERS) Competitors $7.85 -0.04 (-0.51%) Closing price 04:00 PM EasternExtended Trading$7.78 -0.07 (-0.89%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XERS vs. CRSP, TGTX, CYTK, AAPG, KRYS, ACAD, ADMA, TLX, PCVX, and PTCTShould you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), Cytokinetics (CYTK), Ascentage Pharma Group International (AAPG), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), Telix Pharmaceuticals (TLX), Vaxcyte (PCVX), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry. Xeris Biopharma vs. Its Competitors CRISPR Therapeutics TG Therapeutics Cytokinetics Ascentage Pharma Group International Krystal Biotech ACADIA Pharmaceuticals ADMA Biologics Telix Pharmaceuticals Vaxcyte PTC Therapeutics Xeris Biopharma (NASDAQ:XERS) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Is XERS or CRSP more profitable? Xeris Biopharma has a net margin of -13.01% compared to CRISPR Therapeutics' net margin of -1,229.43%. Xeris Biopharma's return on equity of 0.00% beat CRISPR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xeris Biopharma-13.01% N/A -8.00% CRISPR Therapeutics -1,229.43%-20.05%-17.09% Do insiders & institutionals believe in XERS or CRSP? 42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 6.5% of Xeris Biopharma shares are owned by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, XERS or CRSP? Xeris Biopharma has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Do analysts prefer XERS or CRSP? Xeris Biopharma presently has a consensus target price of $7.08, indicating a potential downside of 9.77%. CRISPR Therapeutics has a consensus target price of $71.60, indicating a potential upside of 30.51%. Given CRISPR Therapeutics' higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than Xeris Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83CRISPR Therapeutics 1 Sell rating(s) 7 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.47 Which has preferable earnings & valuation, XERS or CRSP? Xeris Biopharma has higher revenue and earnings than CRISPR Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXeris Biopharma$203.07M6.24-$54.84M-$0.21-37.38CRISPR Therapeutics$37.31M133.73-$366.25M-$5.43-10.10 Does the media favor XERS or CRSP? In the previous week, CRISPR Therapeutics had 7 more articles in the media than Xeris Biopharma. MarketBeat recorded 20 mentions for CRISPR Therapeutics and 13 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.31 beat CRISPR Therapeutics' score of 1.06 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 10 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryXeris Biopharma beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks. Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XERS vs. The Competition Export to ExcelMetricXeris BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.27B$2.56B$5.77B$9.91BDividend YieldN/A50.34%6.71%4.52%P/E Ratio-37.3823.0375.5426.08Price / Sales6.24569.11480.4288.52Price / CashN/A167.8736.9659.01Price / Book-39.255.5011.446.09Net Income-$54.84M$32.95M$3.28B$266.14M7 Day Performance0.26%2.69%0.84%0.28%1 Month Performance43.25%7.87%7.15%4.14%1 Year Performance210.28%0.79%59.66%23.93% Xeris Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XERSXeris Biopharma3.6125 of 5 stars$7.85-0.5%$7.08-9.8%+198.9%$1.27B$203.07M-37.38290News CoveragePositive NewsAnalyst DowngradeShort Interest ↓CRSPCRISPR Therapeutics3.4087 of 5 stars$54.13-0.3%$71.60+32.3%+17.1%$4.94B$37.31M-9.97460TGTXTG Therapeutics4.3257 of 5 stars$28.53-3.1%$46.25+62.1%+44.4%$4.67B$329M77.11290Positive NewsCYTKCytokinetics4.0142 of 5 stars$37.01-3.5%$71.58+93.4%-9.4%$4.59B$18.47M-7.26250Trending NewsAnalyst ForecastInsider TradeOptions VolumeAAPGAscentage Pharma Group InternationalN/A$43.48-9.2%N/AN/A$4.45B$134.35M0.00600Positive NewsGap UpHigh Trading VolumeKRYSKrystal Biotech4.8894 of 5 stars$146.77-2.5%$210.38+43.3%-19.5%$4.36B$290.52M29.83210Positive NewsACADACADIA Pharmaceuticals3.9603 of 5 stars$25.32-1.6%$28.88+14.0%+52.8%$4.34B$957.80M19.04510ADMAADMA Biologics3.7616 of 5 stars$17.01-4.4%$27.67+62.6%+0.2%$4.25B$426.45M19.78530Positive NewsTLXTelix PharmaceuticalsN/A$12.20-2.2%$22.33+83.1%N/A$4.22B$516.72M0.00N/APCVXVaxcyte2.763 of 5 stars$30.45-5.7%$136.50+348.3%-70.5%$4.19BN/A-7.41160News CoveragePositive NewsPTCTPTC Therapeutics4.0554 of 5 stars$49.30-2.5%$69.15+40.3%+72.7%$4.02B$806.78M7.071,410News CoverageAnalyst Forecast Related Companies and Tools Related Companies CRSP Alternatives TGTX Alternatives CYTK Alternatives AAPG Alternatives KRYS Alternatives ACAD Alternatives ADMA Alternatives TLX Alternatives PCVX Alternatives PTCT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XERS) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XERS Stock Alerts